• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed by Verrica Pharmaceuticals Inc.

    7/15/22 4:15:28 PM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VRCA alert in real time by email
    SC 13D 1 tm2221117d1_sc13d.htm SC 13D

     

    UNITED STATES 

    SECURITIES AND EXCHANGE COMMISSION 

    Washington, D.C. 20549

     

    SCHEDULE 13D

     

    Under the Securities Exchange Act of 1934 

    (Amendment No. )*

     

    Verrica Pharmaceuticals Inc. 

    (Name of Issuer)

     

    Common Stock, $0.0001 par value per share 

    (Title of Class of Securities)

     

    92511W108 

    (CUSIP Number)

     

    Paul B. Manning 

    c/o PBM Capital Group, LLC 

    200 Garrett Street, Suite S 

    Charlottesville, VA 22902 

    (434) 980-8100 

    (Name, Address and Telephone Number of Person 

    Authorized to Receive Notices and Communications)

     

    July 5, 2022 

    (Date of Event Which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ¨

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

     

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

    CUSIP No.   92511W108
    1.

    Names of Reporting Persons

     

    Paul B. Manning

    2. Check the Appropriate Box if a Member of a Group (See Instructions)
     

    (a)

     

    (b)

    ¨

     

    x

    3. SEC Use Only
    4.

    Source of Funds (See Instructions)

     

    PF

    5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)    ¨
    6.

    Citizenship or Place of Organization

     

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    7.

    Sole Voting Power

     

    13,907,762 (1)

    8.

    Shared Voting Power

     

    1,481,719 (2)

    9.

    Sole Dispositive Power

     

    13,907,762 (1)

    10.

    Shared Dispositive Power

     

    1,481,719 (2)

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    15,389,481 (3)

    12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)    ¨
    13.

    Percent of Class Represented by Amount in Row (11)

     

    37.4% (4)

    14.

    Type of Reporting Person (See Instructions)

     

    IN

     

    (1)Consists of: (i) 13,651,128 shares of the Issuer’s common stock held by Paul and Diane Manning, JTWROS; and (ii) 256,634 shares of the Issuer’s common stock held by PBM Capital Investments, LLC.

     

    (2)Consists of 1,481,719 shares of the Issuer's common stock held by BKB Growth Investments, LLC.

     

    (3)Consists of: (i) 13,651,128 shares of the Issuer's common stock held by Paul and Diane Manning, JTWROS; (ii)  256,634 shares of the Issuer's common stock held by PBM Capital Investments, LLC; and (iii) 1,481,719 shares of the Issuer's common stock held by BKB Growth Investments, LLC.

     

    (4)This percentage is calculated based upon 41,094,053 shares of the Issuer’s common stock outstanding as of July 8, 2022, as reported by the Issuer to the Reporting Persons on July 11, 2022.

     

    2

     

    CUSIP No.   92511W108
    1.

    Names of Reporting Persons

     

    PBM Capital Investments, LLC

    2. Check the Appropriate Box if a Member of a Group (See Instructions)
     

    (a)

     

    (b)

    ¨

     

    x

    3.

    SEC Use Only

     

    4.

    Source of Funds (See Instructions)

     

    AF

    5.

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)    ¨

    6.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    7.

    Sole Voting Power

     

    256,634

    8.

    Shared Voting Power

     

    0

    9.

    Sole Dispositive Power

     

    256,634

    10.

    Shared Dispositive Power

    0

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    256,634

    12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)    ¨
    13.

    Percent of Class Represented by Amount in Row (11)

     

    0.6% (1)

    14.

    Type of Reporting Person (See Instructions)

     

    OO

     

    (1)This percentage is calculated based upon 41,094,053 shares of the Issuer’s common stock outstanding as of July 8, 2022, as reported by the Issuer to the Reporting Persons on July 11, 2022.

     

    3

     

    CUSIP No.   92511W108
    1.

    Names of Reporting Persons

     

    BKB Growth Investments, LLC

    2. Check the Appropriate Box if a Member of a Group (See Instructions)
     

    (a)

     

    (b)

    ¨

     

    x

    3. SEC Use Only
    4.

    Source of Funds (See Instructions)

     

    AF

    5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)    ¨
    6.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    7.

    Sole Voting Power

     

    1,481,719

    8.

    Shared Voting Power

     

    0

    9.

    Sole Dispositive Power

     

    1,481,719

    10.

    Shared Dispositive Power

     

    0

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,481,719

    12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)    ¨
    13.

    Percent of Class Represented by Amount in Row (11)

     

    3.6% (1)

    14.

    Type of Reporting Person (See Instructions)

     

    OO

     

    (1)This percentage is calculated based upon 41,094,053 shares of the Issuer’s common stock outstanding as of July 8, 2022, as reported by the Issuer to the Reporting Persons on July 11, 2022.

     

    4

     

    Item 1.Security and Issuer

     

    The class of equity securities to which this statement on Schedule 13D relates is the Common Stock, $0.0001 par value per share (“Common Stock”) of Verrica Pharmaceuticals Inc., a Delaware corporation (the “Issuer”). The address of the principal executive offices of the Issuer is 44 West Gay Street, Suite 400, West Chester, PA 19380. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable.

     

    Item 2.Identity and Background

     

    (a)This Schedule 13D is filed by Paul B. Manning (“Mr. Manning”), PBM Capital Investments, LLC, a Delaware Limited Liability Company (“PBM”) and BKB Growth Investments, LLC, a Delaware Limited Liability Company (“BKB” and, with Mr. Manning and PBM, collectively, the “Reporting Persons”).

     

    (b)The principal business office of Mr. Manning and PBM is c/o PBM Capital Group, LLC, 200 Garrett Street, Suite S, Charlottesville, VA 22902. The principal business office of BKB is c/o Tiger Lily Capital, LLC, 200 Garrett Street, Suite O, Charlottesville, VA 22902.

     

    (c)The principal occupation of Mr. Manning is chief executive officer of PBM Capital Group, LLC, a private equity investment firm. The principal business purpose of PBM and BKB is making private investments.

     

    (d)During the last five years, none of the Reporting Persons has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

     

    (e)During the last five years, none of the Reporting Persons was a party to a civil proceeding of a judicial of administrative body of competent jurisdiction or were subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

    (f)Each of PBM and BKB was organized in the state of Delaware and Mr. Manning is a citizen of the United States.

     

    Item 3.Source and Amount of Funds or Other Consideration

     

    On July 5, 2022 Paul and Diane Manning, JTWROS (the “Purchasers”) purchased 4,761,904 shares in a public offering (the “2022 Public Offering”) at an aggregate purchase price of $9,999,998.40.

     

    The funds used by the Purchasers to acquire the securities described above were obtained from the Purchasers’ personal funds.

     

    Item 4.Purpose of Transaction

     

    The Reporting Persons acquired beneficial ownership of the Common Stock reported herein for investment purposes, and such acquisitions were made in the Reporting Persons’ ordinary course of business. The Reporting Persons filed an initial Schedule 13G on February 6, 2019, which filing was amended on February 3, 2020, February 16, 2021 and February 14, 2022 (as amended, the “Schedule 13G”). The Reporting Persons are filing this Schedule 13D to supersede the Schedule 13G.

     

    Except as set forth herein and except that the Reporting Persons or any of their affiliates may, from time to time or at any time, subject to market conditions and other factors, purchase additional Common Stock in the open market, in privately negotiated transactions or otherwise, or sell at any time all or a portion of the Common Stock now owned or hereafter acquired by them to one or more purchasers, as of the date of this Schedule 13D, none of the Reporting Persons has any present plans which relate to or would result in:

     

    (a)The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer;

     

    (b)An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries;

     

    (c)A sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries;

     

    5

     

    (d)Any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board;

     

    (e)Any material change in the present capitalization or dividend policy of the Issuer;

     

    (f)Any other material change in the Issuer’s business or corporate structure including but not limited to, if the Issuer is a registered closed-end investment company, any plans or proposals to make any changes in its investment policy for which a vote is required by section 13 of the Investment Company Act of 1940;

     

    (g)Changes in the Issuer’s charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person;

     

    (h)Causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association;

     

    (i)A class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Act; or

     

    (j)Any action similar to any of those enumerated above.

     

    Mr. Manning has served on the board of directors of the Issuer since December 2015. As a director of the Issuer, Mr. Manning may have influence over the corporate activities of the Issuer, including activities which may relate to the transactions described in clauses (a) through (j) of this Item 4.

     

    Item 5.Interest in Securities of the Issuer

     

    (a) – (b)As of the date hereof, Paul and Diane Manning, JTWROS are the record owners of 13,651,128 shares of the Issuer’s common stock. Mr. Manning exercises sole voting and dispositive power over such shares.

     

    As of the date hereof, PBM is the record owner of 256,634 shares of the Issuer’s common stock. Mr. Manning is the Chief Executive Officer of PBM and has sole voting and dispositive power over the shares held by PBM.

     

    As of the date hereof, BKB is the record owner of 1,481,719 shares of the Issuer’s common stock. Mr. Manning is a co-manager of the manager of BKB and has shared voting and dispositive power over the shares held by BKB.

     

    Each of Mr. Manning, PBM and BKB may be deemed to beneficially own 37.4%, 0.6% and 3.6%, respectively, of the Issuer’s outstanding Common Stock, which percentages are calculated based upon 41,094,053 shares of the Issuer’s common stock outstanding as of July 8, 2022, as reported by the Issuer to the Reporting Persons on July 11, 2022.

     

    Collectively, the Reporting Persons beneficially own an aggregate of 15,389,481 shares of Common Stock, which represents 37.4% of the Issuer's outstanding Common Stock.

     

    (c)Except as set forth herein, none of the Reporting Persons has effected any transactions in shares of the Issuer’s Common Stock during the last 60 days.

     

    (d)Except as set forth herein, no other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, the shares of Common Stock beneficially owned by any of the Reporting Persons.

     

    (e)Not applicable.

     

    Item 6.Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

     

    Investors’ Rights Agreement

     

    Each of the Reporting Persons is party to that certain Amended and Restated Investors’ Rights Agreement (the “Investors’ Rights Agreement”) by and among the Issuer and certain of its stockholders, dated as of February 20, 2018, which provides the holders of registrable securities (as defined in the Investors’ Rights Agreement) with demand, piggyback and S-3 registration rights. Under the terms of the Investors’ Rights Agreement, holders of registrable securities will have equivalent registration rights with respect to any additional shares of Common Stock acquired by these holders.

     

    6

     

    The registration rights granted under the Investors’ Rights Agreement will terminate upon the earlier of the fifth anniversary of the closing of the Issuer’s initial public offering or a liquidation event.

     

    The foregoing description of the Investors’ Rights Agreement does not purport to be complete and is qualified in its entirety by reference to the Investors’ Rights Agreement, which is attached hereto as Exhibit B and incorporated herein by reference.

     

    Lock-Up Agreements

     

    In connection with the 2022 Public Offering, each of the Reporting Persons signed a lock-up letter agreement (collectively, the “Lock-Up Agreements”) that prohibits each Reporting Person from disposing of or hedging any shares or any securities convertible into or exchangeable for the Issuer’s Common Stock for a period of 90 days following June 29, 2022 without the prior written consent of RBC Capital Markets, LLC. RBC Capital Markets, LLC in its sole discretion may release any of the securities subject to these Lock-Up Agreements at any time without notice.

     

    The foregoing description of the Lock-Up Agreements does not purport to be complete and is qualified in its entirety by reference to the form of Lock-Up Agreement, which is attached hereto as Exhibit C and incorporated herein by reference.

     

    Item 7.Material to be Filed as Exhibits

     

    A.Joint Filing Agreement as required by Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.

     

    B.Amended and Restated Investors’ Rights Agreement by and among the Issuer and certain of its stockholders, dated February 20, 2018 (incorporated by reference to Exhibit 10.1 to the Issuer’s Registration Statement on Form S-1, as amended (Registration No. 333-225104), filed with the SEC on May 22, 2018).

     

    C.Form of Lock-Up Agreement (incorporated by reference to Exhibit A to the Underwriting Agreement by and between the Issuer and RBC Capital Markets, LLC, dated June 29, 2022 filed as Exhibit 1.1 to the Issuer’s Current Report on Form 8-K (File No. 1-38529), filed with the SEC on July 1, 2022).

     

    7

     

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: July 15, 2022  
         
    /s/ Paul B. Manning   
    Paul B. Manning  
         
    BKB Growth Investments, LLC  
         
    By: Tiger Lily Capital, LLC,   
    its Manager  
         
    By: /s/ Paul B. Manning   
       Name: Paul B. Manning  
      Title: Manager  
         
    By: /s/ Bradford Manning   
       Name: Bradford Manning  
      Title: Manager  
         
    PBM Capital Investments, LLC  
         
    By: PBM Capital Group, LLC   
    its Manager  
         
    By: /s/ Paul B. Manning   
      Name: Paul B. Manning   
      Title: Chief Executive Officer  

     

      ATTENTION  
         
    Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).

     

    8

     

     

    Exhibit(s):

     

    AJoint Filing Agreement

     

    9

     

     

    EXHIBIT A

     

    JOINT FILING AGREEMENT

     

    Pursuant to Rule 13d-1(k)(1) promulgated pursuant to the Securities Exchange Act of 1934, as amended, the undersigned agree that the attached Schedule 13D is being filed on behalf of each of the undersigned.

     

    Dated: July 15, 2022  
         
    /s/ Paul B. Manning   
    Paul B. Manning  
         
    BKB Growth Investments, LLC  
         
    By: Tiger Lily Capital, LLC,   
    its Manager  
         
    By: /s/ Paul B. Manning   
       Name: Paul B. Manning  
      Title: Manager  
         
    By: /s/ Bradford Manning   
       Name: Bradford Manning  
      Title: Manager  
         
    PBM Capital Investments, LLC  
         
    By: PBM Capital Group, LLC   
    its Manager  
         
    By: /s/ Paul B. Manning   
      Name: Paul B. Manning   
      Title: Chief Executive Officer  

     

     

     

    Get the next $VRCA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VRCA

    DatePrice TargetRatingAnalyst
    11/6/2024Buy → Neutral
    H.C. Wainwright
    11/5/2024Outperform → Sector Perform
    RBC Capital Mkts
    7/25/2023$10.00Hold → Buy
    Needham
    3/22/2023$10.00Buy
    Jefferies
    2/13/2023$4.00 → $11.00Sector Perform → Outperform
    RBC Capital Mkts
    5/25/2022$16.00 → $4.00Outperform → Sector Perform
    RBC Capital Mkts
    3/10/2022$20.00Buy
    Brookline Capital
    3/3/2022$20.00 → $18.00Buy
    Needham
    More analyst ratings

    $VRCA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025

      WEST CHESTER, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Tuesday, May 13, 2025, to discuss the Company's financial results for the first quarter ending March 31, 2025, and provide a corporate update. Individuals may participate in the live call via telephone by dialing 1-800-343-4136 (domestic) or 1-203-518-9843 (international) and using the conference ID: VERRICA. Participants are asked to dial in 10 minutes before the start of

      5/7/25 8:00:00 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verrica Pharmaceuticals to Participate in the Citizens Life Sciences Conference in New York

      WEST CHESTER, Pa., April 30, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the Citizens Life Sciences Conference in New York City. Citizens Life Sciences Conference, May 7-8, 2025Event details:Date: Wednesday, May 7, 2025Time: 3:00 pm ETLocation: New York Hilton Midtown, New York Participants may access a live webcast of the event by clicking the link here. The webcast can also be accessed in the Invest

      4/30/25 8:00:00 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verrica Pharmaceuticals Reports Strong Demand-Led Growth in YCANTH® Dispensed Applicator Units in First Quarter 2025

      – Company generated quarterly sequential growth with Q1 YCANTH® dispensed applicator units rising above 10,000 for the first time in a quarter – – As YCANTH distributor inventory levels have normalized, Company expects that dispensed applicator units will now more closely track demand and gross revenue – WEST CHESTER, Pa., April 07, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Company experienced strong demand-led growth for YCANTH® in the first quarter of 2025, with the number of dispensed applicato

      4/7/25 8:00:00 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRCA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Stalfort John A Iii bought 1,123,595 shares and received a gift of 50,000 shares, increasing direct ownership by 168% to 1,873,800 units (SEC Form 4)

      4 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)

      11/26/24 4:15:08 PM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO and President Rieger Jayson bought 280,898 shares and received a gift of 50,000 shares, increasing direct ownership by 60% to 882,826 units (SEC Form 4)

      4 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)

      11/26/24 4:15:13 PM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Manning Paul B bought 22,921,348 shares and gifted 450,000 shares (SEC Form 4)

      4 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)

      11/26/24 4:15:07 PM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRCA
    Financials

    Live finance-specific insights

    See more
    • Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025

      WEST CHESTER, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Tuesday, May 13, 2025, to discuss the Company's financial results for the first quarter ending March 31, 2025, and provide a corporate update. Individuals may participate in the live call via telephone by dialing 1-800-343-4136 (domestic) or 1-203-518-9843 (international) and using the conference ID: VERRICA. Participants are asked to dial in 10 minutes before the start of

      5/7/25 8:00:00 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 11, 2025

      WEST CHESTER, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Tuesday, March 11, 2025, to discuss the Company's financial results for the fourth quarter and full year ending December 31, 2024, and provide a corporate update. Individuals may participate in the live call via telephone by dialing 1-800-445-7795 (domestic) or 1-785-424-1699 (international) and using the conference ID: VERRICA. Participants are asked to dial in 10 minut

      3/3/25 7:00:00 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results

      - Reports YCANTH® revenue, net of $4.9M for second quarter of 2024 along with the expansion of YCANTH's distribution footprint to include Cencora, Inc. as a specialty distributor – - Announces positive preliminary topline results of Phase 2 clinical study of VP-315 for the treatment of patients with basal cell carcinoma – - Continues to progress preparation for global Phase 3 Common Warts trial with initiation expected in 1H 2025 – - Conference Call Scheduled for Today at 8:30 am ET – WEST CHESTER, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical i

      8/14/24 7:45:00 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRCA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Corcoran Gavin

      4 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)

      4/2/25 4:32:51 PM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Corcoran Gavin claimed ownership of 20 shares (SEC Form 3)

      3 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)

      4/2/25 4:31:50 PM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CMO Rosenberg Noah L.

      4 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)

      3/26/25 7:10:45 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRCA
    SEC Filings

    See more
    • SEC Form DEFR14A filed by Verrica Pharmaceuticals Inc.

      DEFR14A - Verrica Pharmaceuticals Inc. (0001660334) (Filer)

      4/30/25 6:06:32 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Verrica Pharmaceuticals Inc.

      8-K - Verrica Pharmaceuticals Inc. (0001660334) (Filer)

      4/25/25 4:21:12 PM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Verrica Pharmaceuticals Inc.

      DEFA14A - Verrica Pharmaceuticals Inc. (0001660334) (Filer)

      4/22/25 7:18:16 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRCA
    Leadership Updates

    Live Leadership Updates

    See more

    $VRCA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $VRCA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more

    $VRCA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition

      – Company reported $0 in product shipments in the third quarter of 2024 and recognized negative net product revenue of $1.9 million, including a provision for product returns of $1.7 million– – Company expects existing distributor inventory to support most demand for dispensed applicator units into the first quarter of 2025 – – Company continues to look for ways to manage expenses and expand access to YCANTH® for the treatment of molluscum contagiosum – – Company announces new senior leadership with appointments of Dr. Jayson Rieger as Chief Executive Officer and John Kirby as Interim Chi

      11/4/24 4:05:00 PM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verrica Pharmaceuticals Reports Second Quarter 2021 Financial Results

      WEST CHESTER, Pa., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the second quarter ended June 30, 2021. "This quarter, we continued to ramp up commercial preparations for the potential FDA approval of VP-102, our lead product candidate for the treatment of molluscum contagiosum, including strengthening our senior leadership team and ensuring patient access to VP-102 through productive dialogue with medical providers and payors," said Ted White, Verrica's President and Chief Executive Officer. "With a

      8/10/21 7:30:00 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verrica Pharmaceuticals Announces Appointment of Terry Kohler as Chief Financial Officer

      Company strengthens management team in anticipation of the potential commercial launch of VP-102, if approved WEST CHESTER, Pa., July 09, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the appointment of Terry Kohler as Chief Financial Officer. Mr. Kohler is a strategic and operational finance leader with over 20 years of commercial business experience, most recently at a global pharmaceutical company with annual revenues over $2 billion. Mr. Kohler is replacing Brian Davis, who is leaving Verrica to pursue other opportunities. "Te

      7/9/21 7:30:00 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Verrica Pharmaceuticals Inc.

      SC 13G/A - Verrica Pharmaceuticals Inc. (0001660334) (Subject)

      12/9/24 6:22:49 PM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Verrica Pharmaceuticals Inc.

      SC 13D/A - Verrica Pharmaceuticals Inc. (0001660334) (Subject)

      11/26/24 4:15:26 PM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Verrica Pharmaceuticals Inc.

      SC 13G/A - Verrica Pharmaceuticals Inc. (0001660334) (Subject)

      11/14/24 9:32:46 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for YCANTH issued to VERRICA PHARMACEUTICALS INC

      Submission status for VERRICA PHARMACEUTICALS INC's drug YCANTH (ORIG-1) with active ingredient CANTHARIDIN has changed to 'Approval' on 07/21/2023. Application Category: NDA, Application Number: 212905, Application Classification: Type 5 - New Formulation or New Manufacturer

      7/21/23 4:54:32 PM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verrica Pharmaceuticals downgraded by H.C. Wainwright

      H.C. Wainwright downgraded Verrica Pharmaceuticals from Buy to Neutral

      11/6/24 6:25:52 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verrica Pharmaceuticals downgraded by RBC Capital Mkts

      RBC Capital Mkts downgraded Verrica Pharmaceuticals from Outperform to Sector Perform

      11/5/24 6:29:20 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verrica Pharmaceuticals upgraded by Needham with a new price target

      Needham upgraded Verrica Pharmaceuticals from Hold to Buy and set a new price target of $10.00

      7/25/23 7:35:00 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care